share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：證券上市註冊聲明
美股SEC公告 ·  08/19 06:43
Moomoo AI 已提取核心訊息
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
2024年8月19日，生物製藥公司Cingulate Inc.向美國證券交易委員會（SEC）提交了S-1表格，申請根據1933年證券法的註冊聲明。此次提交與Lincoln Park Capital Fund，LLC （Lincoln Park）的可售普通股高達100萬股有關。這些股份可能會在各種交易中出售，其中包括普通經紀交易和直接銷售。註冊允許Lincoln Park以市場價或協商價格出售這些股份。Cingulate Inc.不會從Lincoln Park銷售股份中獲得任何收益。該公司以前與Lincoln Park簽訂了購買協議，允許它指揮Lincoln Park購買總額高達1200萬美元的普通股，但需符合某些條件和限制。截至提交日期，Cingulate的普通股和認股權證分別以「CING」和「CINGW」 符號在納斯達克上市。
2024年8月19日，生物製藥公司Cingulate Inc.向美國證券交易委員會（SEC）提交了S-1表格，申請根據1933年證券法的註冊聲明。此次提交與Lincoln Park Capital Fund，LLC （Lincoln Park）的可售普通股高達100萬股有關。這些股份可能會在各種交易中出售，其中包括普通經紀交易和直接銷售。註冊允許Lincoln Park以市場價或協商價格出售這些股份。Cingulate Inc.不會從Lincoln Park銷售股份中獲得任何收益。該公司以前與Lincoln Park簽訂了購買協議，允許它指揮Lincoln Park購買總額高達1200萬美元的普通股，但需符合某些條件和限制。截至提交日期，Cingulate的普通股和認股權證分別以「CING」和「CINGW」 符號在納斯達克上市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息